Articles written by Andrew Leibowitz
One Institution’s Response to the Perioperative Risk of GLP-1 Receptor Agonists
Since approval of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes mellitus, these drugs have become widely prescribed for the specific purpose of weight loss. A recent study estimated that 2% of all adult residents in the area surrounding Mount Sinai Hospital were prescribed one of these agents.
Read the article



